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Abstract
Combination Antiretroviral Therapy (cART) succeeds to control viral
replication in most HIV infected patients. This is normally followed by a
reconstitution of the CD4+ T cells pool; however, this does not happen for
a substantial proportion of patients. For these patients, an immunother-
apy based on injections of Interleukin 7 (IL-7) has been recently proposed
as a co-adjutant treatment in the hope of obtaining long-term reconsti-
tution of the T cells pool. Several questions arise as to the long-term
efficiency of this treatment and the best protocol to apply. Mathematical
and statistical models can help answering these questions.
We develop a model based on a system of ordinary differential equa-
tions and a statistical model of variability and measurement. We can
estimate key parameters of this model using the data from the main stud-
ies for this treatment, the INSPIRE, INSPIRE 2 & INSPIRE 3 trials. In
all three studies, cycles of three injections have been administered; in the
last two studies, for the first time, repeated cycles of exogenous IL-7 have
been administered. Repeated measures of total CD4+ T cells count in 128
patients as well as CD4+Ki67+ T cells count (the number of cells express-
ing the proliferation marker Ki67) in some of them were available. Our
aim was to estimate the possible different effects of successive injections
in a cycle, to estimate the effect of repeated cycles and to assess different
protocols.
The use of dynamical models together with our complex statistical
approach allow us to analyze major biological questions. We found a
strong effect of IL-7 injections on the proliferation rate; however, the effect
of the third injection of the cycle appears to be much weaker than the first
ones. Also, despite a slightly weaker effect of repeated cycles with respect
to the initial one, our simulations show the ability of this treatment of
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maintaining adequate CD4+ T cells count for years. We were also able to
compare different protocols, showing that cycles of two injections should
be sufficient in most cases.
Keywords: CD4, HIV, Interleukin 7, Mechanistic models, Modeling
1 Introduction
Infection by the Human Immunodeficiency Virus (HIV) leads to severe lym-
phopenia and general immune dysfunction. Combination Antiretroviral Ther-
apy (cART) allows controlling viral load in most patients and often leads to an
adequate immune restoration. However, not all patients get a satisfactory im-
mune reconstitution despite undetectable viral load. Sereti et al [1] called these
patients “immunological non responders”; we prefer to call them “immunolog-
ical low responders” because these patients can still experience an increase of
CD4+ T cells count under cART, albeit insufficient.
A treatment based on injections of exogenous Interleukin-7 (IL-7) has been
recently proposed, and is for the moment the only promising approach in this
context (Sereti et al [2], Levy et al [3,4]). Endogenous IL-7 is a cytokine pro-
duced by non-marrow-derived stromal and epithelial cells, and since it was dis-
covered in 1988 (Namen et al [5]), it has been found to play an important role
in peripheral maintenance of T cells (Fry et al [6], Mackall et al [7]). In HIV-
infected patients, a correlation between plasma levels of endogenous IL-7 and
CD4+ T cell counts has already been reported (Beq et al [8]), and different
mechanisms of action of IL-7 regarding regulation of T lymphocytes number
and behavior have been uncovered, as enhancing thymopoiesis (Mackall et al
[7], Okamoto et al [9]), proliferation (Vieira et al [10], Sportes et al [11]) and
survival (Seddon et al [12], Kondrack et al [13]) of CD4+ T cells.
Mathematical representations of the behavior of the immune system in the
context of HIV infection have been useful to describe and quantify biological
processes that are not directly observed; the interaction between HIV virions
and CD4+ T cells was firstly modeled by Ho et al [14] and Perelson et al [15].
For modeling the effect of exogenous IL-7 administration, it is not useful to
model virus concentration (because viral load is undetectable under cART),
but it is necessary to distinguish between quiescent and proliferating cells. In
this context, Thie´baut et al [16] have quantified the contribution of several
biological mechanisms in CD4+ T cells homeostasis. They have studied the
effect of a single cycle of exogenous IL-7. Here, we extend this approach with
a modified statistical model for analyzing repeated cycles, based on data from
3 clinical studies, INSPIRE, INSPIRE 2 and INSPIRE 3. We focus on several
major clinical questions. What is the effect of the different injections in a cycle?
What is the effect of repeated cycles? What is the long-term efficacy of this
therapy in maintaining CD4+ T cells count at a satisfactory level (over 500
cells/µL)? What is the best protocol of injections?
This paper is divided into 7 sections. Section 2 gives an overview of the
INSPIRE studies and the available data. Section 3 describes the main structure
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of the mathematical and statistical models. Section 4 presents and compares
different statistical models: the “basic model” studying the effect of exogenous
IL-7 over a cycle as a whole, the “3 β’s model” allowing the successive injections
of a cycle to have different effects, and the “cycle effect model” investigating
the long term effect when administering repeated cycles. Section 5 compares
results of four possible protocols (varying the number of injections of a cycle)
and predicts their impact on the maintenance of CD4+ T cells count > 500
cells/µL for an average patient. Section 6 explores the possibility of optimizing
the protocol by investigating in simulation the trajectories of CD4+ T cells
count in good and bad responders. Section 7 concludes.
2 Data and materials
2.1 Data source and subjects
The data have been compiled from three phase I/II multicenter studies: IN-
SPIRE (Levy et al [4]), INSPIRE 2 and INSPIRE 3 (Thie´baut et al [17]). These
studies investigated the effect of a purified glycosylated recombinant human In-
terleukin 7 (r-hIL-7) treatment on immune restoration in immunological low
responder patients. All participants were aged ≥ 18 years, were under sta-
ble cART for at least 2 years, presenting CD4+ T cells count between 100-350
cells/µL (100-400 cells/µL for INSPIRE 2), and undetectable viral load for at
least 6 months prior to screening.
In the first study, INSPIRE, 21 patients received three weekly injections (a
“complete cycle”) of r-hIL-7 at different weight-dependent doses: 10, 20 and
30 µg/kg and the main objective was to evaluate the safety of this treatment.
INSPIRE 2 and INSPIRE 3 (with 23 and 84 treated patients, respectively) fur-
ther studied the biological activity (as well as the safety) of repeated cycles of
r-hIL-7 at 20 µg/kg. In this paper, data for all treated patients from the three
studies (N=128) have been included from the time of the first injection. Overall,
197 r-hIL-7 cycles were administered (41 of them were incomplete cycles con-
sisting of 1 or 2 injections). More details are provided in a previous publication
(Thie´baut et al [17]).
2.2 Study design and observations
Within the first INSPIRE study, all patients received complete cycles. They
had clinic visits at weeks 1, 2 and 3 (at the moment of the injections), weeks
4, 5, 6, 9 and 12, and after, one visit every 3 months; see Levy et al [4] for
more information. Among many measured biomarkers, our model uses total
CD4+ T cells count and the number of CD4+ T cells expressing the Ki67 pro-
liferation marker, hereafter called “CD4 count” and “Ki67 count”, respectively.
Measurements of CD4 counts were made at each visit, while Ki67 counts were
only measured at weeks 1, 2, 3, 5 and 12.
For the first twelve patients of INSPIRE 2, clinic visits within the initial
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cycles were scheduled as for the INSPIRE study (for the rest of them, visits at
week 9 were not performed). After, if CD4 counts were found to be below 550
cells/µL in one of the quarterly visits, a new r-hIL-7 cycle was administered
(with the exception of the first 12 patients, who wait a year before receiving a
new cycle). Within these repeated cycles, clinic visits were scheduled at weeks
1, 2 and 3 (at the moment of the injections), weeks 5 and 12, and once again
quarterly visits are made to check the CD4 count. A maximum of 4 cycles within
21 months and a maximum of 3 cycles within 12 months were established, and all
patients have been followed up at least 3 months after the last cycle. CD4 counts
were measured at all visits for all patients, while Ki67 counts were measured
only for the first cycles of the first 12 patients at weeks 1, 2, 3, 5 and 12.
For INSPIRE 3, patients were randomized into two arms: “r-hIL-7 arm”
and “Control arm” with a ratio 3:1 (3 r-hIL-7 : 1 Control). Patients of the
“r-hIL-7 arm” received the same treatment scheme as patients from INSPIRE
2. Patients of the “Control arm” were first followed up without receiving the
r-hIL-7 for one year, and if CD4 count was still below 500 cells/µL, r-hIL-7
treatment was started as for the other group (Thie´baut et al [17]). CD4 counts
were measured at all visits. No Ki67 counts measurements were available.
The total duration of the studies was 12, 24 and 21 months for INSPIRE,
INSPIRE 2 and INSPIRE 3, respectively.
3 Mathematical and statistical structure
3.1 Mathematical and statistical models
Our theoretical framework to describe the dynamics of CD4 and Ki67 counts is
based on the same system of ordinary differential equations (ODE) as proposed
by Thie´baut et al [16]. For patient i this model can be written as:
dQi
dt = λ
i + 2ρiP i − piiQi − µiQQi
dP i
dt = pi
iQi − ρiP i − µiPP i
The initial condition is assumed to be the equilibrium point (specified by
dQi
dt (0) = 0 ,
dP i
dt (0) = 0).
A graphical representation of the system can be found in Figure 1. This
model includes two state variables: P, the concentration of proliferating cells
expressing the Ki67 proliferation marker (CD4+Ki67+) and Q, the concentration
of quiescent cells (CD4+Ki67−). We have also investigated a model with a
feedback term, obtained by multiplying the basic proliferation rate by 1(P i+Qi)ν ,
where ν is a parameter to be estimated. We did not retain this feedback term
because it did not lead to major improvement of the fit while requiring much
more computation time (see Appendix A).
The vector of parameters of the ODE system is ξi = [λi, ρi, pii, µiQ, µ
i
P ].
These parameters have a biological interpretation: λ is the production rate, ρ is
the reversion rate, pi is the proliferation rate and µQ and µP are the mortality
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rates of Q and P cells, respectively. The logarithmic transformation ensures
positivity of these biological parameters: ξ˜
i
= log(ξi).
Figure 1: Graphical representation of the mathematical model
Modeling the variability of the parameters is a crucial ingredient in our model
because it allows to have a joint estimation of parameters across the population
instead of fitting the model patient-by-patient. A mixed-effect model can be
assumed for each transformed parameter l, l = 1,...,p (here p = 5):
ξ˜il (t) = φl + β
>
l z
i
l (t) + u
i
l
where φl is the intercept, βl is a vector of regression coefficients, z
i
l is a vector of
explanatory variables, and uil are random effects assumed to be independently
and identically normally distributed. Thus, the parameters can vary between
subjects, but also with time through the time-dependent explanatory variables.
In practice, for parsimony, random effects and explanatory variables are included
for a subset of the parameters.
In this paper, we present and discuss several of these variability models. The
random effects have been applied on λ and ρ: uiλ ∼ N (0, σ2λ), uiρ ∼ N (0, σ2ρ) for
all the models. The explanatory variables used are functions of the dose and of
the timing of the r-hIL-7 injections and are used to model the proliferation rate
(pi) and the mortality rate (µQ). These choices are based on many trials and on
previous results of the literature (as in Thie´baut et al [16]).
We also need a model for the observations. The state variables (P i(t), Qi(t))
are not directly observable; we only have discrete-time observations of some
functions of the components of this vector. Let Yi1j and Y
i
2k be the CD4 count
and the Ki67 count for patient i at time tij and tik, respectively. The following
observation scheme is assumed:{
(Yi1j)
0.25 = (P i(tij) +Q
i(tij))
0.25 + i1j
(Yi2k)
0.25 = P i(tik)
0.25 + i2k
with independently normally distributed measurement errors: i1j ∼ N (0, σ2CD4),
i2k ∼ N (0, σ2P ). Note that the times of observations may be different for the
two observed components; indeed there were less observations of Ki67 counts
than of CD4 counts.
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3.2 Inference
The vector θ to be estimated includes the intercepts of the biological parameters
(φλ, φρ, φpi, φµQ , φµP ), the regression coefficients (βpi, βµQ), the variances of the
random effects (σλ, σρ) and the variances of the measurement errors (σCD4, σP ).
As in Guedj et al [18], first the individual likelihoods given the random effects
can be computed; then, the individual likelihoods are computed by integrating
over the random effects via the adaptive Gaussian quadrature (Genz et al [19],
Pinheiro et al [20]); the global log-likelihood is the sum of the individual log-
likelihoods. The parameters can then in principle be estimated by maximum
likelihood. However, due to identifiability problems, it is useful to adopt an
approximate Bayesian approach, as in Drylewicz et al [21]. The prior distri-
bution pi(θ) allows incorporating prior knowledge taken from the literature. In
such very complex models MCMC algorithm generally fail, so we use an ap-
proximate Bayesian inference, simpler than the INLA approach of Rue et al [22]
which is also difficult to apply here. Bayes theorem gives
log[P (θ | Y )]) = L(θ) + log[pi(θ)] + C,
where P (θ | Y ) is the posterior distribution, L(θ) is the log-likelihood and C is
the normalization constant. The Bernstein-Von Mises theorem (Van der Vaart
[23]) justifies a normal approximation of the posterior (NAP). The NAP can be
computed by maximizing the penalized log-likelihood LP (θ) = L(θ) + log[pi(θ)]
and computing the inverse of the Hessian of −LP (θ), H−1
LP
. Thus, the NAP is
N (θ˜, H−1
LP
(θ˜)).
This computation can be achieved with the NIMROD program (Prague et
al [24]) which uses the so-called RVS algorithm (Commenges et al [25]); paral-
lel computing is implemented to achieve acceptable computation times. Other
approaches have been proposed for fitting ODE-based models: Ramsay et al
[26] proposed a penalized likelihood approach for the trajectories of the state
variables circumventing the need of solving the ODE system, but this approach
has also numerical issues in presence of random effects; Kuhn et al [27] have
proposed the stochastic approximation expectation maximisation (SAEM) al-
gorithm which can also be used for maximising a log-likelihood or a penalized
log-likelihood. One advantage of the RVS algorithm is the possibility of com-
puting a stringent stopping criterion. See Appendix B for details.
3.3 Comparison of different models
Here, we present more than one possible statistical model to describe the effect
of r-hIL-7 on biological parameters. To compare them, apart direct likelihood
comparison and individual fits, we use an approximate cross-validation crite-
rion, LCVa, proposed by Commenges et al [28]. LCVa is an extension of Akaike
criterion (AIC), similar to the General Information Criterion (GIC) (Konishi et
al [29]) that corrects not only for the number of parameters but also for the pe-
nalization; LCVa is normalized on the number of observations (see Commenges
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et al [30,31] for further developments). This criterion is:
LCVa =− n−1[ L(θ˜)− Trace(H−1LP (θ˜)HL(θ˜))],
where HL is the Hessian of minus the log-likelihood. Since LCVa estimates
a “risk” (cross-entropy or Kullback-Leibler risk equivalently), the smaller the
better. Differences in criteria values between two models can be considered as
“large” beyond 0.1 when the response is univariate. However, when the response
is multivariate, the threshold for considering a difference as “large” should be
higher, because LCVa, as defined here, is normalized on the number of subjects
and does not take into account the number of observations per subject.
4 Main results
4.1 Basic model: A cycle as a whole entity
Firstly, we are interested in estimating the global effect of the first cycle of
r-hIL-7. To begin with, only first received cycles for each patient have been
considered. As in Thie´baut et al [16] the effect of r-hIL-7 is considered to be
dose-dependent. In our case, we have chosen a to consider a power of the dose
(as is common in pharmacology), that was fixed as 0.25 par profile likelihood
(that is, the fourth root of the dose).
The effect on proliferation pi is taken into account during 7 days (this time
was also fixed by profile likelihood) after each injection. Besides, the effect on
the mortality rate µQ is considered to be constant from two days after the first
injection during twelve months, followed by a linear decrease during another
twelve months. As already mentioned, random effects are added on the produc-
tion rate λ and the reversion rate ρ. Let di the dose received for patient i, and
let Nit the number of injections that patient i has received until time t. The
statistical description for this first model is as follows:
p˜ii(t) = p˜i0 + βpi d
0.25
i 1{Nit−Nit−7=1}
λ˜i(t) = λ˜0 + u
i
λ
µ˜iQ(t) = µ˜Q0 + βµQ d
0.25
i f(t)
ρ˜i(t) = ρ˜0 + u
i
ρ
µ˜iP (t) = µ˜P0
where 1{Nit−Nit−7=1} is an indicator function taking value 1 if an injection has
been administrated in the last 7 days, and
f(t) =
 1 if 2 < t ≤ 3601− (t− 360)/360 if 360 < t ≤ 720
0 if 720 < t
(1)
Taking the same priors as Thie´baut et al [16], we ran the analysis with the
NIMROD program. The results are displayed in Table 1; r-hIL-7 injections
increase the proliferation rate (pi) from 0.041 per day at baseline to 0.135 per
7
day during 7 days after each injection (for the dose equal to 20 µg/kg). Also
the estimated mortality rate of Q cells decreases from 0.104 per day at baseline
to 0.072 during the first year after the treatment.
Table 1: Priors and estimated mean and standard deviation (sd) of all parame-
ters (in logarithmic and natural scales) for the “basic” model when considering
only the first cycle for all patients from INSPIRE 1, 2 & 3; Penalized (P) and
Non Penalized (NP) likelihoods, and LCVa criteria
PRIOR POSTERIOR POSTERIOR
(log-scale) (log-scale) (natural-scale)
mean sd mean sd mean sd
λ 1.000 1.000 2.967 0.062 19.440 1.196
ρ 0.000 0.250 0.680 0.095 1.973 0.187
pi -4.000 1.000 -3.185 0.115 0.041 0.005
µQ -3.600 0.500 -2.264 0.073 0.104 0.008
µP -2.500 0.500 -1.550 0.202 0.212 0.043
βpi 0.997 0.058
βµQ -0.305 0.020
σλ 0.254 0.025
σρ 0.534 0.096
σCD4 0.254 0.003
σP 0.299 0.023
P likelihood -338.7
NP likelihood -327.4
LCVa 2.558
4.2 3 β’s model: A cycle as three different injections
Here we focus on a major question: Have all the three injections the same
quantitative effect on proliferation of CD4+ T cells? Or, more accurately, what
is the role of every single injection in the whole effect of a cycle? For this model
too, we only consider the first received cycle for each patient.The statistical
model for pi was:
p˜ii(t) = p˜i0 +
3∑
k=1
1{Nit=k} βpik d
0.25
i 1{Nit−Nit−7=1}
The results are displayed in Table 2. The quantitative effects of the succes-
sive injections are not equal. They are all significantly different from zero; the
first and second one are similar but the effect of the third one is considerably
weaker. With this model there is a noticeable improvement with respect to the
previous one (LCVa is equal to 2.136 vs 2.558).
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Table 2: Priors and estimated mean and standard deviation (sd) of all parame-
ters (in logarithmic and natural scales) for the “3 β’s” model when considering
only the first cycle for all patients from INSPIRE 1, 2 & 3; Penalized (P) and
Non Penalized (NP) likelihoods, and LCVa criteria
PRIOR POSTERIOR POSTERIOR
(log-scale) (log-scale) (natural-scale)
mean sd mean sd mean sd
λ 1.000 1.000 2.355 0.087 10.541 0.920
ρ 0.000 0.250 0.635 0.102 1.887 0.192
pi -4.000 1.000 -3.306 0.125 0.037 0.005
µQ -3.600 0.500 -2.617 0.080 0.073 0.006
µP -2.500 0.500 -2.187 0.258 0.112 0.029
βpi1 1.155 0.079
βpi2 1.120 0.081
βpi3 0.622 0.073
βµQ -0.239 0.022
σλ 0.267 0.025
σρ 0.575 0.108
σCD4 0.241 0.003
σP 0.305 0.025
P likelihood -279.8
NP likelihood -273.3
LCVa 2.136
4.3 Cycle effect model: Effect of successive cycles
Among the 128 treated patients from all the three studies, 74 have received
more than one cycle. A key question is: Have these repeated cycles the same
quantitative effect with respect to initial ones? CD4 counts are higher before
starting repeated cycles. Also, antibodies anti-r-hIL-7 could appear after an ini-
tial cycle, modifying the effect of r-hIL-7 when cycles are repeated. The second
goal of this paper is to estimate possible quantitative differences in repeated
versus initial cycles. To make this possible, we included data from all received
cycles and we estimated a new fixed effect: the “cycle effect” βC . We keep the
notation ti1 for the time when patient i receives the first injection of a cycle. If
C(t) counts the number of cycles received at time t, let 1C(t)>1 be 1 if a cycle
has been received before time t, 0 otherwise. The cycle effect is incorporated
into the statistical model of proliferation rate as follows:
p˜ii(t) = p˜i0 +
[
βC1{C(t)>1} +
3∑
k=1
1{Nit=k} βpik d
0.25
i
]
1{Nit−Nit−7=1}
The results are displayed in Table 3. The posterior distribution of the cycle
effect βC has mean equal to -0.163 and standard deviation equal to 0.015. In
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other words, the cycle effect is found to be significantly negative. In natural
scale, the effect on proliferation rate for successive cycles is found to be e−0.163
= 0.85 times the effect of the first cycle. The biological interpretation of the
cycle effect is not yet clearly explained. One explanation may be that the first
cycle has modified the reaction of the immune system to further injections; one
possibility is that antibodies against IL-7 decrease the efficient concentration of
IL-7 obtained at the target. However, we must take into consideration differ-
ences in mean CD4 count before the initial and repeated cycles. The mean CD4
count at baseline was 266 cells/µL whereas it was 456 cells/µL before repeated
cycles. Considering the homeostatic regulation of the population of CD4+ cells,
that prevents CD4 counts from exceeding 1200-1300 cells/µL, a feedback mech-
anism may explain an apparent cycle effect. With the aim to deeper study
this phenomenon, we have incorporated a feedback term (see Appendix A). We
found that a feedback effect could indeed be detected, but this had no major
influence on the estimate of the cycle effect.
Table 3: Priors and estimated mean and standard deviation (sd) of all pa-
rameters (in logarithmic and natural scales) for the “cycle effect” model when
considering all cycles for all patients from INSPIRE 1, 2 & 3; Penalized (P) and
Non Penalized (NP) likelihoods, and LCVa criteria
PRIOR POSTERIOR POSTERIOR
(log-scale) (log-scale) (natural-scale)
mean sd mean sd mean sd
λ 1.000 1.000 1.672 0.061 5.323 0.326
ρ 0.000 0.250 0.892 0.093 2.440 0.226
pi -4.000 1.000 -2.853 0.074 0.058 0.004
µQ -3.600 0.500 -2.610 0.068 0.074 0.005
µP -2.500 0.500 -2.567 0.200 0.077 0.015
βpi1 0.931 0.042
βpi2 0.707 0.043
βpi3 0.229 0.042
βµQ -0.082 0.006
βC -0.163 0.015
σλ 0.243 0.026
σρ 0.515 0.084
σCD4 0.289 0.003
σP 0.281 0.019
P likelihood -618.6
NP likelihood -609.4
LCVa 4.762
Appendix C and D show some fits of real data from INSPIRE 2 and 3
obtained with this model. Individual predicted trajectories were computed using
the Parametric Empirical Bayes (PEB) for the parameters having a random
effect (λ and ρ). Several protocols have been compared in the next Section by
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means of this model.
5 Comparing different protocols for an average
patient
We have used the “cycle effect model” to compare different administration pro-
tocols of r-hIL-7 containing complete and incomplete cycles. We always assumed
that CD4 counts are measured every three months, and a new cycle is admin-
istered when CD4 count < 550 cells/µL for 4 years. We examined four possi-
bilities: in protocol A, the patient always receives complete cycles; in protocol
B, the patient receives a first complete cycle followed by repeated cycles com-
posed of two injections; in protocol C the patient receives a first complete cycle
followed by repeated cycles of one single injection; in protocol D the patient
always receives 2-injection cycles (including the initial one).
The protocols were compared according to three criteria computed over a
four-year period: number of injections and cycles received, median CD4 count
over the follow-up and time spent below 500 cells/µL. The criteria were com-
puted for an average patient having both random effects equal to zero (equilib-
rium values of 272 and 6.3 for CD4 and Ki67 counts, respectively).
The results are displayed in Table 4, and we can observe the expected tra-
jectories in Figure 2.
A complete cycle followed by 2-injection cycles (Protocol B) could lead to
similar results than Protocol A in terms of median CD4 count, with the non neg-
ligible advantage that Protocol B requires 15 injections instead of 21. Protocol
C ensures and identical time spent under 500 cells/µL with only 10 injections,
but achieves a median CD4 count lower than Protocol A. Protocol D is also
slightly worse than Protocol A in terms of time below 500 cells/µL.
6 Adaptive protocols: towards a personalized
medicine
Let a patient beginning the r-hIL-7 treatment with a first cycle during which we
collect several CD4 count measurements in order to know the value of his random
effects. This information can be used to calculate the expected trajectories of
this patient when applying the 4 previous protocols. We have taken individual
information for two real patients from INSPIRE 2 and INSPIRE 3 studies and
we want to compare what would be the best protocol for them.
Firstly, we have chosen a patient having a very good response in terms of
CD4 count. For this patient, the value of the parameters including random
effects are equal to λ = 6.586 and ρ = 4.797 (all the other parameters are the
population parameters obtained in the “cycle effect” model).
In Figure 3 we predict the expected trajectories and Table 5 displays the four
criteria for this patient. According to our model, there are only minor differences
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Table 4: Comparison of the number of injections and cycles received, time
under 500 CD4 count and median CD4 count for a patient with RE equal to
zero for the four protocols through four years. In protocol A, the patient always
receives complete cycles; in protocol B, the patient receives a first complete
cycle followed by repeated cycles composed of two injections; in protocol C the
patient receives a first complete cycle followed by repeated cycles of one single
injection; in protocol D the patient always receives 2-injection cycles (including
the initial one)
A B C D
Number of injections received 21 15 10 14
Number of cycles received 7 7 8 7
Time under 500 CD4/µL (days) 60 73 60 87
Median CD4 count 678 663 588 654
between the four protocols for this patient for the four criteria. Protocol B
would spare 2 injections with little impact on the CD4 count and even Protocol
C would be admissible.
We have chosen another patient having a particularly poor response to the
r-hIL-7 treatment. In this case, the value of the parameters including random
effects is equal to λ = 3.284 and ρ = 1.956.
Figure 4 displays the expected trajectories for the different protocols and
Table 6 gives the four criteria for this patient. Our model predicts that this pa-
tient could benefit from 2-injection cycles (protocol B) without loss of efficiency
in terms of CD4 count or time over 500 cells/µL. However, 1-injection cycles
(Protocol C) would not be enough.
7 Discussion
INSPIRE 2 and INSPIRE 3 are the first studies where repeated cycles of r-hIL-7
were administrated to test the long-term restoration of the immune system in
low immunological responders. Here we have used a simple mathematical model
with complex statistical approaches to model the effect of these repeated cycles
on CD4+ T cells concentration. We worked with two CD4+ T cells populations:
quiescent and proliferating (presenting the Ki67+ marker).
When considering every injection separately, the first important result of
this paper is that our model predicts a decreasing effect of successive injections
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Figure 2: CD4 count (cells/µL) predictions for 4 years for a patient having biρ =
biλ = 0. Protocols A, B and C include a first complete cycle followed by: com-
plete cycles (A), two-injection cycles (B) and one-injection cycles (C). Protocol
D includes only 2-injection cycles. Vertical dotted lines are CD4 count assess-
ments (every three months) and vertical solid lines are injections. Horizontal
line marks the CD4 threshold of 550 cells/µL.
on proliferation rate; the third injection seems to have a weaker effect. We
also found that the effect of repeated cycles on proliferation rate was slightly
weaker than the effect of the initial one; the order of magnitude, however, is the
same. This can be due to the natural homeostatic regulation of CD4+ T cells,
since repeated cycles start at a higher CD4 count. In order to investigate this
question, we have introduced a feedback term; in this case the feedback term
slightly improved the fit but the estimate of the “cycle effect” did not change
much. Thus although a feedback mechanism is plausible, there may be other
reason, such as the presence of antibodies, for a slightly weaker effect of repeated
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Figure 3: CD4 count (cells/µL) predictions for 4 years for a particularly good
responder patient. Protocols A, B and C include a first complete cycle fol-
lowed by: complete cycles (A), two-injection cycles (B) and one-injection cycles
(C). Protocol D includes only 2-injection cycles. Vertical dotted lines are CD4
count assessments (every three months) and vertical solid lines are injections.
Horizontal line marks the CD4 threshold of 550 cells/µL.
cycles.
Simulations show how these repeated cycles are able to maintain adequate
CD4 counts for a long time. We have compared four protocols and shown
that cycles of two injections should be sufficient, sparing a certain number of
injections without detrimental effect on CD4 count. Our results agree with a
survival analysis presented in Thie´baut et al [17] who compared the time spent
over 500 cells/µL after a 3-injection cycle and a 2-injection cycle.
Also, the inclusion of random effects is a key ingredient when consider-
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Table 5: Comparison of the number of injections and cycles received, time
under 500 CD4 count and median CD4 count for a ”good responder” patient
for the four protocols through four years. In protocol A, the patient always
receives complete cycles; in protocol B, the patient receives a first complete
cycle followed by repeated cycles composed of two injections; in protocol C the
patient receives a first complete cycle followed by repeated cycles of one single
injection; in protocol D the patient always receives 2-injection cycles (including
the initial one)
A B C D
Number of injections received 9 7 5 6
Number of cycles received 3 3 3 3
Time under 500 CD4/µL (days) 3 3 3 g 3
Median CD4 count 721 709 669 703
Table 6: Comparison of the number of injections and cycles received, time
under 500 CD4 count and median CD4 count for a ”bad responder” patient
for the four protocols through four years. In protocol A, the patient always
receives complete cycles; in protocol B, the patient receives a first complete
cycle followed by repeated cycles composed of two injections; in protocol C the
patient receives a first complete cycle followed by repeated cycles of one single
injection; in protocol D the patient always receives 2-injection cycles (including
the initial one)
A B C D
Number of injections received 30 27 18 26
Number of cycles received 10 13 16 13
Time under 500 CD4/µL (days) 561 366 893 381
Median CD4 count 549 617 470 611
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Figure 4: CD4 count (cells/µL) predictions for 4 years for a patient with a
particularly poor response. Protocols A, B and C include a first complete cycle
followed by: complete cycles (A), two-injection cycles (B) and one-injection
cycles (C). Protocol D includes only 2-injection cycles. Vertical dotted lines
are CD4 count assessments (every three months) and vertical solid lines are
injections. Horizontal line marks the CD4 threshold of 550 cells/µL.
ing dynamic models as assistance for treatment personalized decisions. Inter-
individual differences in parameters imply inter-individual differences in ex-
pected trajectories that can be used for devising adaptive treatment strategies
(Prague et al [32]). We could use this mechanistic model for guiding the treat-
ment, with the aim of minimizing the number of administered injections within
repeated cycles ensuring the expected response. Predictions could also easily be
made for different time lapses between cycles or thresholds for receiving a new
cycle.
Some other questions regarding the interaction between the r-hIL-7 and the
16
immune system could be modeled with additional data. For instance, prefer-
ential effects on specific T cell subsets as recent thymic emigrants (RTEs) and
naive non-RTE T cell populations (Mackall et al [33]) could be analyzed.
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APPENDIX A: Model with a feedback term
Trajectories satisfying an ODE system have an intrinsic tendency to return to
the equilibrium point, when it exists, which is the case for the systems proposed
in this paper. In this sense, a feedback term is not necessary to ensure home-
ostasis, a key concept in physiology. We have, however, considered adding a
feedback term in the mathematical model in order to examine the cycle effect
βC in depth. This term will explicitly avoid CD4
+ T cells to proliferate with-
out control and possibly ensure a faster return to an equilibrium point. The
simplest feedback term is [ 1P+Q ]
ν , and can be added in both equations to the
proliferation term. The system with feedback is as follows:
dQi
dt = λ
i + 2ρiP i − µiQQi − piiQi 1(P i+Qi)ν
dP i
dt = pi
iQi 1
(P i+Qi)ν
− ρiP i − µiPP i
Models with feedback were fitted using the 39 patients of INSPIRE who had
Ki67 count measurements. The feedback coefficient was estimated at ν = 0.119.
In Table 7 we compare some models with and without feedback term.
Table 7: Comparison of loglikelihoods and LCVa criteria of models with and
without feedback for all INSPIRE patients with CD4 and Ki67 count measure-
ments (N=39)
WITHOUT FEEDBACK WITH FEEDBACK
Basic model 3 β’s model Basic model 3 β’s model
NP loglike -44.643 -36.549 -41.735 -36.419
P loglike -49.393 -41.306 -46.965 -41.015
LCVa 1.146 0.940 1.073 0.963
The feedback term does not lead to a great improvement of the LCVa crite-
rion, especially for the 3 β’s model.
The detection of a cycle effect raises anew the issue of a possible feedback.
It may be that the feedback could not be detected when starting with very
low CD4 count, but could be more visible when starting at higher CD4 count;
this feedback might explain the apparent cycle effect. To answer this ques-
tion we ran the model for repeated cycles with feedback. With this more
complicated model and larger data set, we could not directly estimate the pa-
rameter ν, so we resort to profile likelihood. Computing the likelihood for
ν = 0.05, 0.1, 0.15, 0.20, 0.25, 0.30 we found that the best likelihood was ob-
tained for ν = 0.1, a value close to what was estimated in the small data set
(ν = 0.119). The results are shown in Table 8.
For the repeated cycles data set, the feedback term leads to an improve-
ment of the LCVa criterion. This may reflect a biological feedback mechanism.
However, this does not modify the cycle effect βC .
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Table 8: Priors and estimated mean and standard deviation (sd) of all pa-
rameters (in logarithmic and natural scales) for the “cycle effect” model when
considering all cycles for each patient including a feedback term with ν = 0.1;
Penalized (P) and Non Penalized (NP) likelihood and LCVa criteria
PRIOR POSTERIOR POSTERIOR
(log-scale) (log-scale) (natural-scale)
mean sd mean sd mean sd
λ 1.000 1.000 0.275 0.157 1.316 0.207
ρ 0.000 0.250 1.052 0.083 2.863 0.238
pi -4.000 1.000 -1.975 0.068 0.139 0.009
µQ -3.600 0.500 -2.538 0.067 0.079 0.005
µP -2.500 0.500 -2.212 0.138 0.109 0.015
βpi1 0.806 0.038
βpi2 0.626 0.037
βpi3 0.212 0.035
βµQ -0.063 0.005
βC -0.153 0.015
σλ -0.608 0.097
σρ -0.440 0.071
σCD4 0.286 0.004
σP 0.301 0.021
P likelihood -598.0
NP likelihood -584.5
LCVa 4.567
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APPENDIX B: Identifiability and convergence
As can be easily verified, both models with and without the feedback term,
present no problems regarding the “theoretical” identifiability (that depends on
the model structure) but even so, they could present “practical” identifiabil-
ity problems as explained in Guedj et al [18]. In fact, practical identifiability
problems are a mix of statistical and numerical problems which are difficult to
disentangle; with scarce information, the variances of the estimators are large,
but it comes also with a flat shape of the log-likelihood, making it difficult to
maximize. The difficulty is enhanced by the fact that there are several lay-
ers of numerical computation needed to compute the likelihood, leading to an
accumulation of numerical errors.
A crucial point in an iterative algorithm is the stopping criteria. Besides
the displacement in the parameter space and the variation of the likelihood
function, another convergence criterion proposed by Commenges et al [25] has
been implemented in NIMROD. It is the Relative Distance to Maximum (RDM)
defined as
RDM(θ(k)) =
UP (θ(k))TG−1(θ(k))UP (θ(k))
p
where UP (·) is the penalized score and G(·) is an approximation of the Hessian
of minus the penalized likelihood. This criterion can be interpreted as the ratio
of the numerical error over the statistical error, and is asymptotically invariant
near the maximum to any one-to-one transformation of the parameters. Prague
et al [24] propose 0.1 as a good default value.
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APPENDIX C: Some fits of total CD4+ T cell
counts
Figure 5: Cycle effect model : Fits of total CD4 count for 12 patients from
INSPIRE 2 and 3 chosen randomly among those who received more than a
cycle.
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APPENDIX D: Some fits of CD4+Ki67+ T cells
Figure 6: Cycle effect model : Fits of Ki67 count for 6 patients from INSPIRE
and INSPIRE 2 chosen randomly among those who had measurements for this
biomarker (only during the first cycle).
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